Austria's Pharmig supports health reforms

16 September 2007

The Association of the Austrian Pharmaceutical Industry (Pharmig) has responded to proposals by the government's Audit Office President Josef Moser for health care reforms, aimed at saving 2.9 billion euros ($4.0 billion). Pharmig secretary general Jan Oliver Huber complained that "constructive suggestions are rejected from the beginning by some interest groups" within the health care system. Dr Huber said: "what I miss in this whole discussion is the necessary objectivity with which all participants should communicate." He added that "it would be much more meaningful if all partners in the health service sat around a table, in order to discuss necessary structural changes."

Among the problems listed by the drug industry representative was that, "in our health service, there is too much federalism." Health care management needs to be centralized in order to coordinate financing, Dr Huber continued. The urgency of reform, Pharmig believes, comes from the aging population of Austria and the ensuing stretching of health care capacity when faced with accelerating demand.

"No new taxes" Pharmig chief says

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight